792-793 / 1983
ACT IV: Phase 3
•
745 pts
•
HR = 0.99
•
“the rindopepimut combination showed OS data similar to
expectations in the phase III study while patients in the control arm
significantly outperformed.”
•
Reanalysis of EORTC trial patient who met enrolment criteria showed
this better analysis
•
RCTs are not perfect…. But better than this